QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$51.79
-0.1%
$53.32
$43.38
$62.88
$7.01B1.081.14 million shs1.09 million shs
Haemonetics Co. stock logo
HAE
Haemonetics
$84.21
-0.8%
$78.42
$70.74
$95.26
$4.28B0.36444,185 shs273,091 shs
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$155.96
$155.74
$93.34
$156.22
$10.30B0.55656,912 shsN/A
NovoCure Limited stock logo
NVCR
NovoCure
$12.46
-2.0%
$15.00
$10.87
$83.60
$1.33B0.421.37 million shs906,771 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$210.07
-0.1%
$239.43
$180.93
$348.67
$8.13B0.51343,538 shs232,495 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
+0.27%-2.58%+0.80%-6.36%-9.96%
Haemonetics Co. stock logo
HAE
Haemonetics
-0.36%-0.46%+13.49%+2.67%+0.15%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00%0.00%0.00%0.00%0.00%
NovoCure Limited stock logo
NVCR
NovoCure
-6.26%-10.30%-9.01%+1.03%-79.72%
Penumbra, Inc. stock logo
PEN
Penumbra
-3.35%-4.49%-5.39%-20.11%-24.30%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Globus Medical, Inc. stock logo
GMED
Globus Medical
4.6897 of 5 stars
3.31.00.04.12.14.23.1
Haemonetics Co. stock logo
HAE
Haemonetics
4.2167 of 5 stars
2.34.00.04.32.41.72.5
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
2.2884 of 5 stars
0.00.01.73.81.11.72.5
NovoCure Limited stock logo
NVCR
NovoCure
4.5526 of 5 stars
4.34.00.04.52.62.50.0
Penumbra, Inc. stock logo
PEN
Penumbra
4.9205 of 5 stars
4.43.00.03.82.12.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.67
Moderate Buy$66.3328.08% Upside
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$104.6724.29% Upside
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
N/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
2.56
Moderate Buy$31.13149.80% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.78
Moderate Buy$304.4544.93% Upside

Current Analyst Ratings

Latest PEN, HAE, GMED, NVCR, and HRC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/10/2024
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $28.00
4/3/2024
NovoCure Limited stock logo
NVCR
NovoCure
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$49.00 ➝ $42.00
4/3/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$290.00
3/27/2024
NovoCure Limited stock logo
NVCR
NovoCure
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$21.00
3/27/2024
NovoCure Limited stock logo
NVCR
NovoCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$22.00 ➝ $24.00
3/22/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$290.00 ➝ $280.00
3/19/2024
NovoCure Limited stock logo
NVCR
NovoCure
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$15.00 ➝ $17.00
3/18/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$60.00
2/23/2024
NovoCure Limited stock logo
NVCR
NovoCure
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$14.00 ➝ $15.00
2/23/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$310.00 ➝ $290.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.02B6.87$3.62 per share14.32$29.32 per share1.77
Haemonetics Co. stock logo
HAE
Haemonetics
$1.17B3.66$4.92 per share17.13$16.22 per share5.19
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$3.02B3.41$9.29 per share16.79$28.56 per share5.46
NovoCure Limited stock logo
NVCR
NovoCure
$509.34M2.62N/AN/A$3.39 per share3.68
Penumbra, Inc. stock logo
PEN
Penumbra
$1.06B7.68$2.73 per share76.90$30.55 per share6.88

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$122.87M$1.1744.2715.791.527.83%8.82%7.20%5/2/2024 (Estimated)
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4634.2319.862.019.97%22.37%9.71%5/9/2024 (Confirmed)
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$207.04M-$1.95N/AN/AN/A-40.65%-51.63%-17.90%5/2/2024 (Confirmed)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$2.3190.9452.782.158.59%7.49%5.60%5/7/2024 (Confirmed)

Latest PEN, HAE, GMED, NVCR, and HRC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88N/A-$0.88N/AN/AN/A  
5/7/2024N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$0.42N/A-$0.42N/AN/AN/A  
5/2/2024N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$0.42N/A+$0.42N/AN/AN/A  
2/22/2024Q4 2023
NovoCure Limited stock logo
NVCR
NovoCure
-$0.53-$0.45+$0.08-$0.45$133.80 million$133.80 million      
2/22/2024Q4 2023
Penumbra, Inc. stock logo
PEN
Penumbra
$0.71$0.76+$0.05$0.14$286.62 million$284.68 million      
2/20/2024Q4 2023
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.59$0.60+$0.01$1.09$608.21 million$616.53 million    
2/8/202412/31/2023
Haemonetics Co. stock logo
HAE
Haemonetics
$0.94$1.04+$0.10$1.47$320.84 million$336.20 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$0.960.62%N/A25.81%N/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.10
4.88
2.72
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.97
1.38
1.05
NovoCure Limited stock logo
NVCR
NovoCure
1.57
5.78
5.56
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.06
3.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
76.45%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
24.30%
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.69%
NovoCure Limited stock logo
NVCR
NovoCure
5.67%
Penumbra, Inc. stock logo
PEN
Penumbra
5.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
5,000135.37 million102.48 millionOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
10,00066.05 million65.59 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,453107.09 million101.02 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,20038.70 million36.65 millionOptionable

PEN, HAE, GMED, NVCR, and HRC Headlines

SourceHeadline
10,800 Shares in Penumbra, Inc. (NYSE:PEN) Bought by Louisiana State Employees Retirement System10,800 Shares in Penumbra, Inc. (NYSE:PEN) Bought by Louisiana State Employees Retirement System
marketbeat.com - April 16 at 6:51 AM
Critical Review: Penumbra (NYSE:PEN) vs. ProSomnus (NASDAQ:OSA)Critical Review: Penumbra (NYSE:PEN) vs. ProSomnus (NASDAQ:OSA)
americanbankingnews.com - April 16 at 1:32 AM
Raymond James & Associates Sells 4,167 Shares of Penumbra, Inc. (NYSE:PEN)Raymond James & Associates Sells 4,167 Shares of Penumbra, Inc. (NYSE:PEN)
marketbeat.com - April 15 at 4:26 AM
Allspring Global Investments Holdings LLC Buys 42,876 Shares of Penumbra, Inc. (NYSE:PEN)Allspring Global Investments Holdings LLC Buys 42,876 Shares of Penumbra, Inc. (NYSE:PEN)
marketbeat.com - April 11 at 6:50 AM
Recap: Heres what happened with the April 8 solar eclipse in VirginiaRecap: Here's what happened with the April 8 solar eclipse in Virginia
13newsnow.com - April 10 at 11:17 PM
Baillie Gifford & Co. Sells 31,674 Shares of Penumbra, Inc. (NYSE:PEN)Baillie Gifford & Co. Sells 31,674 Shares of Penumbra, Inc. (NYSE:PEN)
marketbeat.com - April 10 at 8:24 AM
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024
finance.yahoo.com - April 9 at 8:37 PM
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024
prnewswire.com - April 9 at 4:05 PM
Total solar eclipse 2024: Watch video and see photos of the sky spectacleTotal solar eclipse 2024: Watch video and see photos of the sky spectacle
msn.com - April 9 at 10:36 AM
Celestial event: What you need to know about todays total solar eclipseCelestial event: What you need to know about today's total solar eclipse
msn.com - April 8 at 2:23 PM
Heres Why You Should Retain Penumbra (PEN) Stock for NowHere's Why You Should Retain Penumbra (PEN) Stock for Now
zacks.com - April 8 at 10:35 AM
Monday’s Solar Eclipse: Chicago to Witness Partial Sun Obscuration, Southern Illinois to Experience TotalityMonday’s Solar Eclipse: Chicago to Witness Partial Sun Obscuration, Southern Illinois to Experience Totality
msn.com - April 7 at 5:06 AM
Penumbra director sells $37,940 in company stockPenumbra director sells $37,940 in company stock
uk.investing.com - April 5 at 6:45 PM
What is an umbra? A penumbra? Heres some terms to know ahead of the 2024 solar eclipseWhat is an umbra? A penumbra? Here's some terms to know ahead of the 2024 solar eclipse
news.yahoo.com - April 5 at 6:45 PM
‘Nervous’ parents beg NYC officials to do more to protect kids during solar eclipse‘Nervous’ parents beg NYC officials to do more to protect kids during solar eclipse
msn.com - April 5 at 3:43 AM
Edge of solar eclipse path of totality may slightly shift, experts warnEdge of solar eclipse path of totality may slightly shift, experts warn
msn.com - April 5 at 3:43 AM
Insider Sell: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ...Insider Sell: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ...
finance.yahoo.com - April 4 at 12:38 PM
Insider Selling: Penumbra, Inc. (NYSE:PEN) Director Sells 170 Shares of StockInsider Selling: Penumbra, Inc. (NYSE:PEN) Director Sells 170 Shares of Stock
insidertrades.com - April 4 at 6:52 AM
Insider Selling: Penumbra, Inc. (NYSE:PEN) EVP Sells 600 Shares of StockInsider Selling: Penumbra, Inc. (NYSE:PEN) EVP Sells 600 Shares of Stock
insidertrades.com - April 4 at 6:41 AM
Inmates sue prison for right to watch solar eclipse, claiming it’s a religious experienceInmates sue prison for right to watch solar eclipse, claiming it’s a religious experience
forward.com - April 4 at 12:02 AM
Eclipse 2024: What to expect here in MichiganEclipse 2024: What to expect here in Michigan
msn.com - April 4 at 12:02 AM
A Sense of Agency: A Conversation with Lauren OylerA Sense of Agency: A Conversation with Lauren Oyler
theparisreview.org - April 3 at 2:01 PM
How do flat-earthers explain a total solar eclipse?How do flat-earthers explain a total solar eclipse?
msn.com - April 3 at 2:01 PM
Penumbra (NYSE:PEN) Rating Reiterated by Piper SandlerPenumbra (NYSE:PEN) Rating Reiterated by Piper Sandler
marketbeat.com - April 3 at 12:14 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Globus Medical logo

Globus Medical

NYSE:GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Hill-Rom logo

Hill-Rom

NYSE:HRC
Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.
NovoCure logo

NovoCure

NASDAQ:NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Penumbra logo

Penumbra

NYSE:PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.